Meglucon (Metformin Hydrochloride)

• Meglucon (metformin) is used to manage disorders of glucose metabolism, primarily type 2 diabetes and related conditions.
• Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose.
• Impaired glucose tolerance (prediabetes): delays progression to overt diabetes by reducing hepatic glucose output.
• Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity in some patients.

• Metformin exerts its antihyperglycaemic effect primarily by inhibiting mitochondrial respiratory‑chain complex I in hepatocytes, which reduces hepatic gluconeogenesis. The resulting decrease in hepatic glucose production, together with enhanced peripheral glucose uptake and utilization, improves insulin sensitivity in muscle and adipose tissue. Metformin does not stimulate insulin secretion, thereby lowering the risk of hypoglycaemia when used alone, and may modestly affect lipid profiles.

Metformin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite.
• Diarrhoea: frequent loose stools, especially at treatment initiation.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight over time.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate, presenting with rapid breathing and muscle pain.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Vitamin B12 deficiency: may develop with long‑term therapy, leading to neuropathy.

Before initiating Meglucon, several safety considerations should be evaluated.

• Renal function assessment: ensure estimated glomerular filtration rate is ≥45 mL/min/1.73 m² before starting.
• Hepatic status review: avoid use in patients with severe liver disease.
• Monitor blood glucose: adjust dose based on glycaemic response and avoid hypoglycaemia when combined with other agents.
• Elderly patients: start at lower dose and monitor for accumulation due to reduced renal clearance.
• Contrast imaging precaution: discontinue metformin at least 48 hours before and after iodinated contrast studies in patients with impaired renal function.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase risk of lactic acidosis.
• Cimetidine: can raise plasma metformin concentrations, increasing toxicity risk.
• Alcohol excess: enhances lactate production and raises lactic acidosis risk.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask symptoms of hypoglycaemia.
• Diuretics (especially thiazides): can affect renal function and metformin clearance.
• ACE inhibitors or ARBs: monitor renal function and electrolytes when combined.